Jaguar Health issues 481,584 shares to Streeterville to cut note balance

Jaguar Health, Inc. disclosed in an 8-K that on September 25, 2026 it entered into exchange agreements with Streeterville Capital, LLC covering a secured promissory note originally issued in 2021. The note was issued and sold to Streeterville on January 19, 2021 in an original principal amount of $6,220,812.50 under a Note Purchase Agreement between the two parties dated the same day.¹

Under the new agreements, Jaguar issued 481,584 shares of its common stock to Streeterville, lowering the note's outstanding balance by $3,400,000.¹ The company said the exchange agreements contain representations, warranties, and covenants that are standard for this type of transaction.¹

The shares were not registered. Jaguar stated that the shares were issued under the exemption from registration available under Section 3(a)(9) of the Securities Act of 1933.¹

Following the transaction, Jaguar reported approximately 1,945,542 shares of common stock issued and outstanding as of September 25, 2026.¹

Separately, in a 424B5 prospectus supplement dated September 24, 2026, Jaguar disclosed terms of its at-the-market offering program. The aggregate market value of the company's common stock held by non-affiliates as of September 23, 2026 was approximately $44,172,183, based on 1,281,839 outstanding shares held by non-affiliates and a closing price of $34.46 per share on September 22, 2026.² Jaguar said it had sold about $4,899,873 worth of shares under the applicable Form S-3 instruction during the trailing 12-month period ending on the date of the filing.² As a result, the company said it may sell up to approximately $9,824,188 in additional shares through its sales agent under the current prospectus.² On September 23, 2026, the last reported sale price of Jaguar's common stock on Nasdaq was $8.91 per share.²